---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-251386"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:30:17.864221+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Equillium files Metacrine financials and pro forma statements for pending merger

## Summary
- Metacrine 2021 net loss $62.2M; accumulated deficit $182.95M as of Dec 31, 2021.
- Audited financials for 2021 and 2020, plus unaudited interim statements through June 30, 2022 filed.
- Unaudited pro forma combined balance sheet as of June 30, 2022 reflects the acquisition.
- Updated risk factor disclosure filed as Exhibit 99.3 to supplement prior filings.

## SEC filing metadata
- accession: 0001193125-22-251386
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312522251386/0001193125-22-251386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312522251386/d382206d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-251386
- JSON: https://secwatch.observer/filing/0001193125-22-251386.json
- Plain text: https://secwatch.observer/filing/0001193125-22-251386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.